Paxman (PAX.ST) Stock Analysis & AI Equity Report
Paxman (PAX.ST) overview
Paxman (PAX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Paxman reported revenue of SEK 313m and operating profit of SEK 4.3m; the year-end share price was 56.20 SEK and market capitalisation was SEK 1,237m. Paxman is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Paxman's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Paxman
Paxman AB develops and markets scalp cooling systems used during chemotherapy to help reduce hair loss in cancer patients. The company sells its Paxman and DigniCap systems to hospitals, clinics and treatment centres, and also provides related installation, service and support. Its business is driven by global device sales and recurring treatment-related demand.
Generate the Paxman report
Paxman is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Paxman and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.